Eurofins will distribute Synthego's sgRNA products to its customers in 44 countries.
The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.
The system combines sample preparation technology capable of amplifying tens of thousands of locations in the genome with next-generation sequencing.
Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests.
An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.
The deal will close in July and will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing.
The deal is expected to expand Eurofin's clinical diagnostic footprint in Europe.
The lab was opened earlier this year as the company's central genomics lab in North America, offering various genomic services such as DNA sequencing.
The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
In Science this week: the synthetic genetic system hachimoji, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.